KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBITDA Margin (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of EBITDA Margin data on record, last reported at 37.8% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 257.0% year-over-year to 37.8%; the TTM value through Dec 2025 reached 34.77%, up 3689.0%, while the annual FY2025 figure was 34.77%, 3689.0% up from the prior year.
  • EBITDA Margin reached 37.8% in Q4 2025 per VRTX's latest filing, down from 38.56% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 53.15% in Q3 2021 and bottomed at 132.85% in Q2 2024.
  • Average EBITDA Margin over 5 years is 30.8%, with a median of 40.72% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: crashed -17402bps in 2024, then skyrocketed 17168bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 42.35% in 2021, then grew by 6bps to 44.88% in 2022, then fell by -13bps to 39.26% in 2023, then fell by -10bps to 35.23% in 2024, then grew by 7bps to 37.8% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 37.8% in Q4 2025, 38.56% in Q3 2025, and 38.83% in Q2 2025.